About Transmembrane and immunoglobulin domain-containing protein 1
Transmembrane and immunoglobulin domain-containing protein 1 (TMIGD1) is a protein
from Homo sapiens identified by UniProt accession
Q6UXZ0, 262 residues long.
MolForge cross-references it against 0 known binders and
51 disease associations.
Target properties
| Protein name | Transmembrane and immunoglobulin domain-containing protein 1 |
|---|
| UniProt accession | Q6UXZ0 |
|---|
| Gene | TMIGD1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 262 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (51)
Diseases linked to this target (Open Targets).
- apolipoprotein A 1 measurement · score 0.31
- smoking status measurement · score 0.28
- intelligence · score 0.11
- breast milk measurement · score 0.09
- neoplasm · score 0.08
- renal cell carcinoma · score 0.08
- kidney neoplasm · score 0.07
- lean body mass · score 0.06
- Meckel's diverticulum · score 0.05
- GIST-plus syndrome · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6UXZ0-F1 | alphafold | PREDICTED | 87.84 | — |
Amino-acid sequence (262 residues)
MAWKSSVIMQ MGRFLLLVIL FLPREMTSSV LTVNGKTENY ILDTTPGSQA SLICAVQNHT REEELLWYRE EGRVDLKSGN KINSSSVCVS SISENDNGIS FTCRLGRDQS VSVSVVLNVT FPPLLSGNDF QTVEEGSNVK LVCNVKANPQ AQMMWYKNSS LLDLEKSRHQ IQQTSESFQL SITKVEKPDN GTYSCIAKSS LKTESLDFHL IVKDKTVGVP IEPIIAACVV IFLTLCFGLI ARRKKIMKLC MKDKDPHSET AL
Explore Transmembrane and immunoglobulin domain-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets